Jointown obtains drug registration for key injection

Jointown Pharmaceutical Group (SSE:600998) announced that its subsidiary, Huiyu Yuanhe (Hainan) Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Betamethasone Sodium Phosphate Injection. This approval signifies that the drug meets relevant registration requirements and allows for its production and distribution. Betamethasone Sodium Phosphate Injection, a corticosteroid, is used to treat allergic and autoimmune inflammatory diseases. Data shows the injection has a growing market with China's public medical institutions, with sales exceeding CNY 220 million in 2023. The approval will expand Jointown's market share and enrich its injectable product line, strengthening the company's competitive position. In 2024, Jointown achieved CNY 30.07 billion in sales of its products and OEM business.